the impact of systemic therapy and keynote-048 trial
Published 5 years ago • 135 plays • Length 5:48Download video MP4
Download video MP3
Similar videos
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
1:19
dr. lee on the impact of immunotherapy in head and neck cancer
-
5:16
danny rischin, asco 2019 - phase iii keynote-048 trial
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
1:55
dr. burtness on findings of keynote-048 in head and neck cancer
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
1:09
the future role of immunotherapy in head and neck cancers
-
1:18
keynote-048 trial
-
3:55
checkpoint inhibitors for recurrent hnscc
-
1:06
dr. cohen discusses the keynote-040 trial in head and neck cancer
-
4:24
historic perspective on recurrent hnscc
-
11:47
pembrolizumab in hnscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
4:24
mike gibson, asco 2019 - keynote-062 and keynote-48 trial data
-
1:17
dr. ferris on fda approval of nivolumab in patients with head and neck cancer